(Registrieren)

EANS-Adhoc: SOLON SE / Restructuring of SOLON SE Management Board completed - new directors appointed for the operations and sales divisions

Geschrieben am 15-12-2010


--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------


Company Information

15.12.2010

Restructuring of SOLON SE Management Board completed -
new directors appointed for the operations and sales divisions

Berlin, December 15, 2010. Dr. Martin Detje is to become the new
chief operating officer (COO) responsible for SOLON SE´s operations
division with effect from January 1, 2011. Dr. Detje (49), who holds
a doctorate in physics, started his career at Omicron Vakuumphysik
GmbH. He was initially located in Japan for several years, where he
set up a local service network before becoming product manager. In
2001, he joined Infineon Technologies AG (subsequently Qimonda AG),
where one of his roles was to establish an R&D center at the
company´s Dresden site. He then became head of operations and
projects at Qimonda Solar GmbH before heading up its research and
development department. Most recently, he was responsible for the
turnkey production lines business at global solar energy company Roth
und Rau AG. At the same time, he held the position of managing
director at its subsidiary Roth und Rau Ortner GmbH, which
specializes in production logistics and automation solutions for the
photovoltaics industry. Dr. Detje is married with two children.

SOLON's current COO, Dr. Gero Wiese, is to resign his directorship
and leave the company at the end of the year by mutual consent with
the Supervisory Board. He is currently in negotiations regarding an
executive role with a company in which SOLON SE holds a stake. The
Supervisory Board would like to thank Dr. Wiese for his dedication
and excellent service as a member of the SOLON SE Management Board,
particularly his professionalism during the establishment of our
production facilities and in the restructuring phase.

Having launched a marketing and sales campaign this year, SOLON SE´s
Supervisory Board has also decided to appoint a new Management Board
member with sole responsibility for sales. Andreas Amelang has been
recruited for the new role of chief sales officer (CSO), which he
will take up on April 1, 2011. Andreas Amelang (49) has a degree in
marine engineering, and his first position after graduating was as a
project engineer at the MTW Schiffswerft shipyard in Wismar, Germany.
He subsequently joined the Voith group of companies, where he was a
project planning engineer in its global ship propeller sales team. He
later became head of sales/project planning at Voith Turbo Marine
GmbH & Co. KG. In 2004, he joined the Aker Group in Germany as
marketing and sales director for shipyards. He returned to Voith in
2007, where his most recent position was vice president for Voith
radial propellers with responsibility for establishing a new division
for special ship propulsion systems. Andreas Amelang is married and
has one son.

SOLON SE
Therese Raatz
Investor Relations
Tel.: +49 (0)30 818 799 305
Fax: +49 (0)30 818 799 300
Email: therese.raatz@solon.com


end of announcement euro adhoc
--------------------------------------------------------------------------------


ots Originaltext: SOLON SE
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Therese Raatz

Head of Corporate Communications

Tel.: +49 30 818 79-9305

E-Mail: therese.raatz@solon.com

Branche: Energy
ISIN: DE0007471195
WKN: 747119
Index: Midcap Market Index, CDAX, HDAX, Technology All Share, GEX,
ÖkoDAX
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / regulated dealing
Hamburg / regulated dealing
Stuttgart / regulated dealing
Düsseldorf / regulated dealing
München / regulated dealing


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

306435

weitere Artikel:
  • EANS-Adhoc: Basler AG / Vorstand erhöht Prognose für das Geschäftsjahr 2010 -------------------------------------------------------------------------------- Ad-hoc-Meldung nach § 15 WpHG übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- Unternehmen 15.12.2010 - Kamerageschäft übertrifft Erwartungen - Umsatzprognose Geschäftsjahr 2010: 49 - 50 Mio. EUR (vorher 46 - 48 Mio. EUR) - Vorsteuerergebnis-Prognose Geschäftsjahr 2010: >4,6 Mio. EUR (vorher mehr...

  • EANS-Adhoc: Basler AG / Management Board increases guidance for fiscal 2010 -------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Company Information 15.12.2010 - Camera business exceeding expectations - 2010 sales forecast now EUR49 - 50 mill. (was EUR46 - 48 mill.) - 2010 EBT forecast now > EUR4.6 mehr...

  • EANS-News: SYGNIS Pharma AG / SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register -------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Capital measures Heidelberg (euro adhoc) - SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register Heidelberg, 15 December 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) mehr...

  • EANS-News: SYGNIS Pharma AG / Herabsetzung des Grundkapitals der SYGNIS im Verhältnis 3 : 1 im Handelsregister eingetragen -------------------------------------------------------------------------------- Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. -------------------------------------------------------------------------------- Kapitalmaßnahmen Heidelberg (euro adhoc) - Herabsetzung des Grundkapitals der SYGNIS im Verhältnis 3 : 1 im Handelsregister eingetragen Heidelberg, 15. Dezember 2010 - Die SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) gibt mehr...

  • Pressemitteilung betreffend der Klage des Masseverwalters von Bernard Madoff gegen 2020 Medici Klage gegen 2020 Medici (ehemals Bank Medici) ("MEDICI"), Frau Sonja Kohn, Unicredit, Bank Austria und andere in den USA Wien/Österreích (ots) - Die Anschuldigungen, die Herr Irving H. Picard in seiner Klage gegen Medici und Frau Sonja Kohn erhebt, sind gänzlich haltlos, unwahr und entbehren jeder rechtlichen Grundlage. Medici und Frau Sonja Kohn wurden, wie viele andere führende Finanzinstitutionen und erfahrene Anleger, von Madoff betrogen. Weder Medici noch Frau Sonja Kohn waren zu irgendeinem Zeitpunkt Komplizen in Bernard mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht